Dachaigh › Ailsean fala › North Carolina
Sgrùdaidhean clionaigeach Ailsean fala ann an North Carolina
Tha 24 sgrùdaidhean airson Ailsean fala a’ lorg phàirtichean aig làraichean ann an North Carolina.
Bailtean ann an North Carolina
Teacsa sgrùdaidh oifigeil (Beurla)
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Duke Cancer Center Cary, Cary
- Duke University Medical Center, Durham
- East Carolina University, Greenville
- agus 4 a bharrachd
A’ fastadhSgrùdadh amharc
Gach aois · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT04242095Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- WakeMed Cancer Care - Waverly Hematology & Medical Oncology ( Site 0074), Cary
- University of North Carolina at Chapel Hill ( Site 0040), Chapel Hill
- Duke Cancer Center ( Site 0028), Durham
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- agus 6 a bharrachd
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05334069Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 27, Chapel Hill
A’ fastadhÌre 3
Aoisean 18 gu 71 · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07504458Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Duke University, Durham
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Sult 2026 · NCT07648264Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- UNC School of Medicine, Division of Hematology, Chapel Hill
A’ fastadhÌre 1/2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT04588922A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Novant Health Weisiger Cancer Institute, Charlotte
A’ fastadhSgrùdadh amharc
Aoisean 0 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT07154823Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of North Carolina, Chapel Hill, Chapel Hill
- Duke University Medical Center, Durham
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Lùna 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Atrium Health Levine Cancer Center, Charlotte
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Lùna 2026 · NCT06001788DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill
A’ fastadh
Aoisean 60 agus nas sine · Gach gnè · Air ùrachadh 14 Lùna 2026 · NCT06296368A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Levine Cancer Institute, Charlotte
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Lùna 2026 · NCT06823167PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- Lineberger Cancer, Chapel Hill
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Lùna 2026 · NCT06665100ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period
- Levine Cancer Insitute, Charlotte
A’ fastadh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Iuch 2026 · NCT07203534Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment
- 2400 Pratt Street, Durham
A’ fastadh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 8 Iuch 2026 · NCT06532773Implementation of an Oral Chemotherapy Adherence Intervention
- UNC Chapel Hill, Chapel Hill
A’ fastadh
Aoisean 21 agus nas sine · Gach gnè · Air ùrachadh 8 Iuch 2026 · NCT06989489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of North Carolina at Chapel Hill, Chapel Hill
- Levine Children's Hospital, Charlotte
- Duke University Medical Center, Durham
A’ fastadhSgrùdadh amharc
Gach aois · Gach gnè · Air ùrachadh 6 Iuch 2026 · NCT01351545Optimizing Health Related Quality of Life Measurement in Adolescent and Young Adult Oncology
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 15 agus nas sine · Gach gnè · Air ùrachadh 30 Ògmh 2026 · NCT06897137Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of North Carolina, Chapel Hill
A’ fastadhÌre 1
Aoisean 13 agus nas sine · Gach gnè · Air ùrachadh 5 Cèit 2026 · NCT04771572CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Duke University Medical Center, Duke Cancer Center, Durham
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Gibl 2026 · NCT03328078A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Duke Blood Cancer Center, Durham
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Màrt 2026 · NCT05735184HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
- Duke University Health System, Durham
A’ fastadhÌre 1 tràth
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Faoi 2026 · NCT06731504A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
- Levine Cancer Institute, Charlotte
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Ògmh 2025 · NCT05768269IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Atrium Health Wake Forest Baptist, Winston-Salem
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 3 Ògmh 2025 · NCT06119685Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Carolina-Levine Children's Hospital, Charlotte
A’ fastadhÌre 1
Aoisean 1 gu 21 · Gach gnè · Air ùrachadh 6 Dùbh 2024 · NCT05476770Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.